Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
Moodys
Medtronic
Express Scripts
Johnson and Johnson

Last Updated: October 16, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,511,041

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,511,041 protect, and when does it expire?

Patent 7,511,041 protects ALIQOPA and is included in one NDA.

This patent has fifty patent family members in thirty-two countries.

Summary for Patent: 7,511,041
Title:Fused azole-pyrimidine derivatives
Abstract: The present invention relates to hovel fused azolepyrimidine derivatives, processes for preparing them and pharmaceutical preparations containing them. The fused azolepyrimidine derivatives of the present invention exhibit enhanced potency for phosphotidylinositol-3-kinase (PI3K) inhibition, especially for PI3K-.gamma. inhibition and can be used for the prophylaxis and treatment of diseases associated with PI3K and particularly with PI3K-.gamma. activity. More specifically, the azole derivatives of the present invention are useful for treatment and prophylaxis of diseases as follows: inflammatory and immunoregulatory disorders, such as asthma, atopic dermatitis, rhinitis, allergic diseases, chronic obstructive pulmonary disease (COPD), septic shock, joint diseases, autoixnmune pathologies such as rheumatoid arthritis, and Graves' disease, cancer, myocardial contractility disorders, heart failure, thromboembolism, ischemia, and atherosclerosis. The compounds of the present invention are also useful for pulmonary hypertension, renal failure, cardiac hypertrophy, as well as neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease, diabetes and focal ischemia, since the diseases also relate to PI3K activity in a human or animal subject.
Inventor(s): Shimada; Mitsuyuki (Nara, JP), Murata; Toshiki (Nara, JP), Fuchikami; Kinji (Tokyo, JP), Tsujishita; Hideki (Kyoto, JP), Omori; Naoki (Hyogo, JP), Kato; Issei (Nara, JP), Miura; Mami (Nara, JP), Urbahns; Klaus (Lund, SE), Gantner; Florian (Constance, DE), Bacon; Kevin (San Diego, CA)
Assignee: Bayer Pharmaceuticals Corporation (West Haven, CT)
Application Number:10/527,376
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 7,511,041

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bayer Healthcare ALIQOPA copanlisib dihydrochloride POWDER;INTRAVENOUS 209936-001 Sep 14, 2017 RX Yes Yes   Request a Trial   Request a Trial Y Y   Request a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,511,041

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
02021861Sep 30, 2002
PCT Information
PCT FiledSeptember 18, 2003PCT Application Number:PCT/EP03/10377
PCT Publication Date:April 08, 2004PCT Publication Number: WO2004/029055

International Family Members for US Patent 7,511,041

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 041426   Request a Trial
Argentina 072458   Request a Trial
Austria 411996   Request a Trial
Austria 511510   Request a Trial
Australia 2003293310   Request a Trial
Brazil 0314830   Request a Trial
Brazil PI0314830   Request a Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Merck
Johnson and Johnson
Mallinckrodt
McKinsey
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.